ReviewCancer gene therapy2012
Will T-cell therapy for cancer ever be a standard of care?
Review in Cancer gene therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02667093 (Bone Marrow and Peripheral Blood), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Bone Marrow and Peripheral Blood (PB) Samples From Patients With Leukemia and PB From Their BM Donors (BMD) to Identify Leukemia-Specific Antigens (LSA) and Graft Versus Host Disease Antigens (GVHDA) for Use in Cellular Immunotherapy
Who cites it
10 citing papers in PubMed.
- Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013Trial
- Barcoded screening identifies nanocarriers for protein delivery to kidney.Nature communications · 2025Article
- CD4Journal of cancer research and clinical oncology · 2023Article
- Towards a commercial process for the manufacture of genetically modified T cells for therapy.Cancer gene therapy · 2015Review
- Are clinical trials with mesenchymal stem/progenitor cells too far ahead of the science? Lessons from experimental hematology.Stem cells (Dayton, Ohio) · 2014Review
- Past, present and future targets for immunotherapy in ovarian cancer.Immunotherapy · 2014Review
- Gene therapy on the move.EMBO molecular medicine · 2013Review
- Collapse of the tumor stroma is triggered by IL-12 induction of Fas.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
- Immunotherapeutic strategies to target prognostic and predictive markers of cancer.Biomarkers in medicine · 2013Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Cellular therapies for cancer are showing increasing efficacy but their introduction as a 'standard of care' for these disorders is hampered by technical, regulatory and financial concerns. This review identifies some of the major problems and suggests potential solutions.
Indexed as
Identifiers
23059871What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.